← Back to Clinical Trials
Recruiting NCT06406062

NCT06406062 Artificial Intelligence-assisted System in Colonoscopy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06406062
Status Recruiting
Phase
Sponsor Renmin Hospital of Wuhan University
Condition Adenoma Colon Polyp
Study Type OBSERVATIONAL
Enrollment 7,500 participants
Start Date 2024-05-20
Primary Completion 2025-12-30

Eligibility & Interventions

Sex All sexes
Min Age 50 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
ANDOANGEL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 7,500 participants in total. It began in 2024-05-20 with a primary completion date of 2025-12-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

In recent years, computer-aided diagnosis system based on artificial intelligence (AI) has been used in colorectal polyp detection. In recent years, computer-aided diagnosis system based on artificial intelligence (AI) has been used in colorectal polyp detection. However, whether AI-assisted can improve the adenoma-detection rate (ADR) is inconclusive. This study aims to evaluate the real-world performance of an AI system that combines polyp detection with colonoscopy quality control. This study aims to explore the clinical application value of AI-based polyp detection and quality control function by comparing the data of polyp detection rate and adenoma detection rate in multiple centers with and without AI-assisted colonoscopy in a multicenter, prospective real world study. However, whether AI-assisted can improve the adenoma-detection rate (ADR) is inconclusive. This study aims to evaluate the real-world performance of an AI system that combines polyp detection with colonoscopy quality control. This study aims to explore the clinical application value of AI-based polyp detection and quality control function by comparing the data of polyp detection rate and adenoma detection rate in multiple centers with and without AI-assisted colonoscopy in a multicenter, prospective real world study.

Eligibility Criteria

Inclusion Criteria: 1. age \> 50 years old; 2. required diagnostic colonoscopy, screening colonoscopy, or follow-up colonoscopy; 3. voluntarily sign informed consent; 4. Commitment to abide by the study procedures and cooperate with the implementation of the whole process of the study. Exclusion Criteria: 1. have participated in other clinical trials, signed informed consent and are in the follow-up period of other clinical trials; 2. known polyposis syndrome patients; 3. patients with known IBD; 4. patients considered by the investigators to be unsuitable or unable to undergo complete digestive endoscopy and related examinations; 5. high-risk diseases or other special conditions considered by the investigator to be unsuitable for clinical trial participation.

Contact & Investigator

Central Contact

Honggang Yu, Doctor

✉ wjlnsm@163.com

📞 18771146096

Frequently Asked Questions

Who can join the NCT06406062 clinical trial?

This trial is open to participants of all sexes, aged 50 Years or older, studying Adenoma Colon Polyp. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06406062 currently recruiting?

Yes, NCT06406062 is actively recruiting participants. Contact the research team at wjlnsm@163.com for enrollment information.

Where is the NCT06406062 trial being conducted?

This trial is being conducted at Wuhan, China.

Who is sponsoring the NCT06406062 clinical trial?

NCT06406062 is sponsored by Renmin Hospital of Wuhan University. The trial plans to enroll 7,500 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology